ISNES, Belgium, July 10, 2018 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition") today announced
that it has added to its already impressive clinical trial program
with the execution of additional agreements to conduct large-scale
colorectal cancer research studies across the Asia Pacific
Region. These multi-country, multi-center and multi-ethnic
Asian subject cohorts are in addition to the approximate 45,000
European subject cohorts and the 13,500 plus U.S. subject cohorts
that are already part of existing studies and further demonstrate
Volition's commitment to commercializing its Nu.Q™ platform
globally through collaborating with world-renowned institutions and
key opinion leaders.
In accordance with the previously announced memoranda of
understanding, Volition has executed agreements with the
prestigious National Taiwan University ("NTU") to conduct two
studies under the supervision of Professor Han-Mo Chiu, Clinical Professor, Department of
Internal Medicine of NTU, and Professor Takahisa Matsuda, Director of Cancer Screening
Center, National Cancer Screening Hospital, Tokyo, Japan who will act as Co-Principal
Investigator.
The first trial will be a large-scale study in the Asia Pacific
Region, including 5,000 asymptomatic colorectal cancer screening
subjects. The second trial will include up to 2,000 symptomatic
colorectal cancer patients. These studies are being conducted to
test and validate Volition's proprietary Nu.Q™ platform for the
detection and diagnosis of colorectal cancer for marketing, rather
than for regulatory purposes.
Professor Chiu commented, "The early detection of colorectal
cancer could benefit the survival rate of patients significantly.
There is a clear need for a product which not only has high
accuracy but is also easy to use and affordable, such as a routine
blood test. I very much look forward to collaborating with Volition
in evaluating its Nu.Q™ technology platform."
In addition to these large-scale studies with NTU, Volition has
also recently executed an agreement for a 719-subject study in
collaboration with Professor Khay Guan
Yeoh of the National University of
Singapore. The study in Singapore gives an added dimension of
applicability in different Asian ethnic groups by leveraging on the
multi-ethnic population in Singapore.
"We are delighted to be working with such renowned institutions
and prominent thought leaders,"
commented Dr. Jasmine Kway, Chief Executive Officer, Singapore
Volition. "At a cost of approximately $2.55
million payable over three years, these large-scale studies
are in line with Volition's other great value studies and
demonstrate our commitment to conducting large yet cost-effective
trials worldwide to drive the acceptance of our products. These
studies are pivotal for Volition's strategy for the Asia Pacific
Region where incidence of colorectal cancer is increasing."
Ongoing Clinical Studies
Institution
|
Condition
|
Sample
Collection
|
Cohort
|
Early Detection
Research Network of
the U.S. National
Cancer Institute
|
Colorectal
Cancer
|
9,000
Prospective
4,600 Retrospective
|
13,500 +
screening
population
|
Hvidore Hospital,
University of
Copenhagen
|
Colorectal
Cancer
|
Retrospective
|
4,800
symptomatic
|
Hvidore Hospital,
University of
Copenhagen
|
Colorectal
Cancer
|
Prospective
|
14,000 screening
population
|
Hvidore Hospital,
University of
Copenhagen
|
Colorectal
Cancer and
Other
|
Prospective
|
30,000 screening
population
|
National
Taiwan
University
|
Colorectal
Cancer
|
Prospective
|
5,000
Screening
Population
|
National
Taiwan
University
|
Colorectal
Cancer
|
Prospective
|
2,000
Symptomatic
Population
|
University of
Bonn
|
27 Most
Prevalent
Cancers
|
Prospective
|
4,500
subjects
|
German Cancer
Research Center
(DKFZ)
|
Pancreatic
Cancer
|
Retrospective
|
750
subjects
|
About Volition
Volition is a multi-national life sciences company focused on
developing simple, easy to use, cost effective blood tests designed
to help diagnose a range of cancers. The tests are based on
the technology platform of Nucleosomics®, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has
the potential to not only prolong the life of patients, but also to
improve their quality of life. Volition's research and
development activities are currently centered in Belgium, with additional offices in
London, Texas and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
https://volitionrx.com/
or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media/Investor Contacts
Louise
Day, Chief Marketing & Communications Officer
l.day@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice
President, Investor Relations
s.powell@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's bodily-fluid-based diagnostic
tests as well as Volition's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.Q™ and Hypergenomics® and their
respective logos are trademarks and/or service marks of VolitionRx
Limited and its subsidiaries. All other trademarks, service marks
and trade names referred to in this press release are the property
of their respective owners. Additionally, unless otherwise
specified, all references to "$" refer to the legal currency of
the United States of America.
View original
content:http://www.prnewswire.com/news-releases/volition-extends-global-reach-of-its-clinical-trial-program-300678386.html
SOURCE VolitionRx Ltd